Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Mutant RAS has remained recalcitrant to targeted therapy efforts. Here we demonstrate that combined treatment with poly ADP ribose polymerase (PARP) inhibitors and MEK inhibitors evokes unanticipated, synergistic cytotoxic effects in vitro and in vivo in multiple RAS mutant tumor models across tumor...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Sci Transl Med
Κύριοι συγγραφείς: Sun, Chaoyang, Fang, Yong, Yin, Jun, Chen, Jian, Ju, Zhenlin, Zhang, Dong, Chen, Xiaohua, Vellano, Christopher P., Jeong, Kang Jin, Ng, Patrick Kwok-Shing, Eterovic, A. Karina, Bhola, Neil H., Lu, Yiling, Westin, Shannon N, Grandis, Jennifer R., Lin, Shiaw-Yih, Scott, Kenneth L., Peng, Guang, Brugge, Joan, Mills, Gordon B.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5919217/
https://ncbi.nlm.nih.gov/pubmed/28566428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal5148
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια